Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma

BACKGROUND: Sonidegib and vismodegib are Hedgehog pathway inhibitors (HhIs) that play a relevant role in the management of locally advanced basal cell carcinoma (laBCC). This study compared the efficacy and safety of both HhIs based on their available data using effect size measures such as number n...

Descripción completa

Detalles Bibliográficos
Autores principales: García Ruiz, Antonio J, García-Agua Soler, Nuria, Herrera Acosta, Enrique, Zalaudek, Iris, Malvehy, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281973/
https://www.ncbi.nlm.nih.gov/pubmed/35912002
http://dx.doi.org/10.7573/dic.2022-1-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281973/
https://www.ncbi.nlm.nih.gov/pubmed/35912002
http://dx.doi.org/10.7573/dic.2022-1-2

Ejemplares similares